関連ニュース

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal